Onalespib

Overview

Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 ( Hsp90 ) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR , p-EGFR, AKT , P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC).

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HSP

Product Information

• Catalog No.: HY-14463
• CAS No.: 912999-49-6
• Molecular Formula: C24H31N3O3
• Molecular Weight: 409.52
• Purity: 99.11%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution
• Availability: In-stock

Source

Original product source